Saturday 17 October 2026 Export ANIK’s income statement to Excel — free account

Anika Therapeutics Inc.

ANIK Healthcare Drug Manufacturers Specialty & Generic

Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.98 0.71 −3.43%

Follow ANIK

Alert me

Market cap: $276.9M
P/E: 0.0×
Fwd P/E: −20.0×
Dividend yield: —
F-score: 6/9
Altman Z: 3.13
Beneish M: −2.84
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.26

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	1	1	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 5.93%

Capital & Financial Ratios $m

Market Cap 276.90

Revenue 120.65

Net Income (3.78)

Free Cash Flow 0.56

Net Debt (38.41)

Current Ratio 4.48

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (20.00)

P/S ratio 2.21

P/B ratio 1.94

Past 5Y EPS Growth —

This Y EPS Growth 854.55%

Next Y EPS Growth (9.52%)

Next Y revenue growth 7.78%

Next 5Y EPS Growth 118.66%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.58%

10-year low 10-year high

P/B against its own 10 years 53.67%

10-year low 10-year high

EV/Sales against its own 10 years 23.33%

10-year low 10-year high

EV/FCF against its own 10 years 95.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	69	56	57	38
Receivables	26	24	24	29
Inventory	24	24	19	29
Other	36	5	—	—
	163	114	103	99

	2023	2024	2025	Q'26
Payables	6	6	6	6
ST’ Debt	—	—	—	—
Other	11	4	—	—
	31	23	22	22

Compound Annual Growth %

	10y	5y	3y
Sales	1.95%	(2.86%)	(0.30%)
Cash Flow	(11.94%)	(3.05%)	36.40%
Earnings	0.00%	0.00%	0.00%
Book Value	(3.78%)	(12.04%)	(20.50%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	30	33	—	—	—
’25	26	28	28	31	113
’24	29	31	30	31	120
’23	38	44	41	(3)	121
’22	37	40	40	(3)	114
’21	34	38	40	36	148
’20	35	31	32	33	130

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(1)	—	—	—
’25	0	0	7	5	11
’24	0	(1)	5	2	5
’23	(4)	(8)	6	4	(2)
’22	(2)	3	3	0	4
’21	(2)	4	2	4	8
’20	1	4	6	3	13

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(2)	—	—	—
’25	2	(6)	5	4	5
’24	(2)	(4)	4	0	(2)
’23	(5)	(10)	6	2	(7)
’22	(3)	1	1	(2)	(3)
’21	(3)	2	1	3	3
’20	0	3	6	2	11

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.37)	0.24	—	—	—
’25	(0.34)	(0.28)	(0.16)	0.02	(0.76)
’24	(0.31)	(0.01)	(2.03)	(1.50)	(3.83)
’23	(0.71)	(0.19)	(0.45)	(4.30)	(5.64)
’22	(0.20)	(0.20)	(0.29)	(0.34)	(1.02)
’21	0.20	0.45	0.04	(0.40)	0.28
’20	0.40	(0.54)	(0.45)	(1.10)	(1.69)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	35.07	41.64	28.54	29.01	22.01	32.30	19.95	16.54	15.83	7.87	Analyst estimates 2026–2028 Powerpack
	High	54.96	60.29	69.81	75.72	55.10	48.37	36.85	32.33	29.12	18.37
People
People	Employees	122	123	133	154	277	297	345	357	288	235
	Revenue/emp, $m	0.85	0.92	0.79	0.74	0.47	0.50	0.33	0.34	0.42	0.48
Income, $m
Income, $m	Revenue	103	113	106	115	130	148	114	121	120	113
	Gross margin, %	76.76	75.87	70.37	74.92	52.91	56.12	64.33	68.33	63.38	56.56
	EBT	51	46	23	36	(29)	2	4	3	(3)	(9)
	EBT margin, %	49.21	40.74	21.99	31.52	(21.94)	1.64	3.80	2.61	(2.31)	(8.25)
	Net income	33	32	19	27	(24)	4	(15)	(83)	(56)	(11)
	Depreciation	4	4	6	6	67	21	14	76	11	6
Per share, $
Per share, $	Revenue	7.04	7.78	7.31	8.12	9.17	10.26	7.82	8.24	8.15	7.87
	Earnings	2.22	2.18	1.30	1.93	(1.69)	0.29	(1.02)	(5.64)	(3.83)	(0.76)
	Cash flow	1.67	2.80	2.42	2.62	0.92	0.58	0.30	(0.12)	0.37	0.78
	Capex	(0.95)	(0.62)	(0.32)	(0.20)	(0.11)	(0.36)	(0.51)	(0.37)	(0.53)	(0.43)
	Free cash flow	0.71	2.18	2.10	2.42	0.80	0.23	(0.21)	(0.49)	(0.16)	0.35
	Book value	15.17	18.08	18.25	20.42	19.15	19.94	19.61	14.48	10.46	10.01
	Shares, m	15	15	14	14	14	14	15	15	15	14
Valuation, ×
Valuation, ×	P/E	22.57	25.19	25.85	26.87	0.00	123.55	0.00	0.00	0.00	0.00
	P/S	7.12	7.06	4.60	6.39	4.93	3.49	3.77	2.75	2.02	1.22
	P/B	3.30	3.04	1.84	2.54	2.36	1.80	1.50	1.56	1.57	0.96
	EV/Sales	5.91	5.67	3.09	4.96	4.37	3.02	3.23	2.39	1.77	0.93
	EV/FCF	58.56	20.20	10.79	16.64	49.87	137.25	(119.57)	(39.97)	(90.81)	21.22
Cash, $m
Cash, $m	Operating cash flow	24	41	35	37	13	8	4	(2)	5	11
	Capex	(14)	(9)	(5)	(3)	(2)	(5)	(7)	(5)	(8)	(6)
	Free cash flow	10	32	30	34	11	3	(3)	(7)	(2)	5
Balance, $m
Balance, $m	Working capital	162	193	192	218	141	139	142	132	90	81
	Total debt	—	—	—	23	22	21	31	—	—	—
	Net debt	(125)	(157)	(159)	(185)	(98)	(94)	(86)	(69)	(56)	(57)
	Shareholders’ equity	223	263	264	288	272	287	286	212	154	143
Returns, %
Returns, %	ROA	13.68	12.17	6.67	8.92	(6.89)	1.16	(4.27)	(26.68)	(23.82)	(5.54)
	ROIC	32.27	26.90	13.00	20.69	(10.17)	0.85	1.15	0.37	(3.24)	(8.03)
	ROE	15.01	13.09	7.10	9.85	(8.55)	1.48	(5.19)	(33.21)	(30.79)	(7.32)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%
ACB Aurora Cannabis Inc.	$265.8M	— (loss-making)	— (loss-making)	−31.15% (below 0%: shrinking)	n/m	−293.56% (below 0%: shrinking)	52.73%	(12.92%)	Compare
BIOA BioAge Labs, Inc.	$245.6M	— (loss-making)	— (loss-making)	+1.62% (above 0%: growing)	n/m	+2.68% (above 0%: growing)	100.00%	(1,196.78%)	Compare
LFCR Lifecore Biomedical, Inc.	$244.1M	— (loss-making)	— (loss-making)	−6.25% (below 0%: shrinking)	n/m	−117.03% (below 0%: shrinking)	35.34%	7.51%	Compare
SIGA Siga Technologies Inc.	$229.2M	— (loss-making)	28.7×	−49.45% (below 0%: shrinking)	−66.00% (below 0%: shrinking)	−75.95% (below 0%: shrinking)	57.17%	33.91%	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
Median of peers	$255.7M	—	—	−2.31%	—	−82.47%	54.95%	(18.32%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Anika Therapeutics Inc. (ANIK) key facts

Concern: Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024.
Anika Therapeutics Inc. (ANIK) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ANIK traded at $19.98, a market capitalization of $276.9 million.
Return on equity was −7.32% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 3.13 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.